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Abstract—Chemical conjugates between sodium cellulose sulfate (CS), displaying contraceptive and HIV-entry inhibiting properties,
and nucleoside reverse transcriptase inhibitors (NRTIs) (3′-azido-2′,3′-dideoxythymidine (AZT), 3′-fluoro-2′,3′-dideoxythymidine (FLT),
or 2',3'-dideoxy-3'-thiacytidine (3TC)) were designed to simultaneously provide contraceptive and anti-HIV activity. Two linkers, acetate
and succinate, were used to conjugate the nucleoside analogs with CS. The conjugates containing cellulose sulfate-acetate (CSA) (e.g.,
AZT-CSA and FLT-CSA) were found to be more potent than CS and other conjugates (e.g., AZT-succinate-CS, and FLT-succinate-CS).
The presence of both sulfate and the acetate groups on cellulose were critical for generating maximum anti-HIV activity. In addition to
showing equal potency against wild-type and multidrug resistant HIV-1, the AZT-CSA conjugate displayed significant contraceptive
activity in an animal model, providing the initial proof-of-concept for the design and synthesis of dual-activity compounds based on these
combinations.

Unplanned pregnancies and sexually transmitted
infections, including HIV/AIDS, affect millions of
women each year providing the rationale for the
development of novel multi-purpose prevention
technologies.1 Sulfonate and sulfate polyanionic
compounds inhibit HIV entry into host cells2−5 and also
display
sperm-function
inhibiting
properties.6,7
Polyanionic sulfates are polymers, such as dextran,
cellulose, styrene, with sulfate groups in their
structure.3,5,8,9 In our attempt to develop novel dualactivity compounds, we conjugated polyanionic
cellulose derivatives with known HIV nucleoside
reverse transcriptase inhibitors (NRTIs).
The viral envelope protein gp120 is known to have
positively charged residues in its V3 loop. HIV entry in
host cell depends on the virus interactions with the
negatively charged surfaces of the coreceptors CXCR4
and CCR5.10 Polyanionic sulfates exhibit their
inhibitory activity by blocking these interactions.11−14
Different strains of HIV are known to have different
gp120 V3 loops. X4-strains of HIV, for instance,
possess a higher positive charge density on their V3
loop than R5 strains.8,14,15 This property of X4 makes
them more susceptible to polyanionic inhibitors. Certain
polyanionic derivatives like dextran sulfate and heparin
show weak inhibitory activity against R5 HIV strains.
11,16

Sodium cellulose sulfate (Ushercell, CS, 1) is a

polyanionic non-cytotoxic microbicide and its 6% gel
has been studied as a vaginal contraceptive and a broadspectrum antimicrobial agent, both preclinical and
clinically.7,17,18 Similar to other polyanionic derivatives,
CS (1) interacts with the positively charged viral
envelope proteins, and prevents virus cell entry. Various
preclinical studies showed that CS possesses significant
anti-HIV activity against both strains of virus, but it is
more active against X4 tropic than R5 tropic HIV.16,19
In addition to antimicrobial activity, CS also
showed contraceptive activity because of its ability to
inhibit sperm enzymes (e.g., hyaluronidase; IC50 = 1.7
mg/ml), which are important for sperm-egg
interaction.17 CS also inhibits sperm penetration of
cervical mucus.17 In a noncomparative contraceptive
effectiveness trial of 6% CS gel involving 200 couples
who used the product for 6 month as their only method
of contraception, CS showed similar effectiveness rates
to those of commercial spermicides.7
CS showed promising results in the preclinical
studies and phases I and II clinical trials sponsored by
CONRAD. In preclinical studies, CS prevented
conception in rabbits when applied vaginally before
insemination, and was also found to inhibit HIV,
Neisseria
gonorrhoeae,
and
Chlamydia
trachomatis.6,17,20 Results from phase I clinical trials
showed that CS was very safe and non-irritating to
penile and vaginal application.21,22 CS vaginal gel (6%)

was well tolerated as vaginal microbicide in both
healthy and HIV-infected women, producing similar
results to the commercial lubricant K-Y jelly.7,23−25
Despite the promising preclinical results showing
anti-HIV activity, CS failed to protect women in two
large phase 3 clinical trials.18,26 Several hypotheses are
still being investigated, but low antiviral potency and
poor tissue penetration have been suggested as possible
causes for the lack of correlation between clinical and
preclinical results.
The microbicides field has moved on to the
development of more potent and specific compounds,
selecting a few nucleoside and non-nucleoside reverse
transcriptase inhibitors as its lead candidates (e.g.,
tenofovir, dapivirine, and UC781). As a result of such
change, the current candidates display only antiviral
activity and they are more susceptible to develop
resistant viruses. 27 The selective activity of these drugs
against HIV will leave women who have unprotected
intercourse exposed to other sexually transmitted
infections and pregnancy. Although CS is no longer
being developed as an anti-HIV microbicide, it
represents a good candidate to use as proof-of-concept
for a substituted compound with dual, contraceptive and
antimicrobial activity. Evaluation of novel CS
derivatives or conjugates provides insights for designing
the second generation of compounds with more optimal
biological profile.
Therefore, as proof-of-concept for a novel dualactivity compound with potent anti-HIV activity, higher
barrier to resistant virus and contraceptive activity, we
herein report the synthesis and biological evaluation of
bifunctional sodium cellulose sulfate conjugates with
NRTIs, 3′-azido-2′,3′-dideoxythymidine (Zidovudine,
AZT), 3′-fluoro-2′,3′-dideoxythymidine (Alovudine,
FLT), and 2',3'-dideoxy-3'-thiacytidine (Lamivudine,
3TC). Two different linkers (acetate and succinate) were
used to conjugate the nucleoside analogs with CS in
different loading values. Both nucleosides and CS
contain alcohol functional groups and functionalization
with linkers containing carboxylic acids allows
conjugation through the formation of an ester moiety.
Furthermore, it was expected that the ester conjugates
would be cleaved by hydrolytic activity of cellular
esterase enzymes, resulting in two separate components:
CS (HIV entry blocker) and nucleoside analogs
(NRTIs). Conjugates were also expected to exert
contraceptive activity mediated by the released CS.
The synthesis of cellulose sulfate acetate conjugates
of AZT, FLT and 3TC was accomplished using building
block synthetic strategy. For the synthesis of
nucleoside-CSA conjugates, CS (1) was reacted first
with 2-bromoacetic acid in presence of sodium
hydroxide to render cellulose sulfate acetate (CSA, 2).
CSA was then reacted with AZT, FLT, or N4-DMTr3TC to yield cellulose sulfate acetate conjugates of AZT
(3, AZT-CSA, 1.78% loading), FLT (4, FLT-CSA,
1.43% loading), or N4-DMTr-3TC-CSA (5′),
respectively. Deprotection of DMTr group in 5′

afforded 3TC-CSA (5, 1.07% loading) (Scheme 1).
OSO3Na
O
HO

OH
HO
O

OH

OSO3Na OH O

O
HO

NaO3SO
O
O
OH

O
S ONa
O
O
O
O

OH

1
O
Br

OSO3Na
O
HO

OH NaOH, Water

HO
O

O

OSO3Na O

O
HO

OH
O

OSO3Na
O
HO

HO
O

2
ROH
DIC, DMPA, DMSO

O

O
HO

OR
O
NH
N
HO

O

O
X

X = N3 AZT
X = F FLT

O
S ONa
O
O
O
O

OH

OH

OSO3Na O
ROH

OH NaO3SO
O
O
OH

OH

O
NH(DMTr)
N
N O
OH
O
S

OH NaO3SO
O
O
OH

O
S ONa
O
O
O
O

OH

3 ROH = AZT
4 ROH = FLT
5' ROH = N4-DMTr-3TC
ACOH (80%)
5 ROH = 3TC

N4-DMTr-3TC)

Scheme 1. Synthesis of cellulose sulfate acetate conjugates of AZT (3),
FLT (4), and 3TC (5).

For the synthesis of sodium cellulose sulfate
conjugates linked to AZT or FLT through a succinate
linker, AZT and FLT were first reacted with succinic
anhydride to synthesize AZT succinate (6′) and FLT
succinate (7′), which were then reacted with cellulose
sulfate to afford cellulose sulfate succinate conjugates
of AZT (6, 18.48% loading) and FLT (7, 7.87%
loading) (Scheme 2).

Scheme 2. Synthesis of AZT-succinate-CS (6) and FLT-succinate-CS (7)
conjugates.

The percentage of the loaded nucleosides on the

polymer through the acetate or succinate linkers was
determined using the size exclusion chromatography
(SEC) method based on the calibration curves of
different concentrations of nucleosides versus area
under the curve. The polymer-nucleoside conjugates
were eluted at 9.15-9.50 min. It was assumed that the
nucleosides were mainly conjugated through acetate or
succinate linkers to the more reactive primary alcohols,
but conjugation on secondary alcohols through linkers
may also contribute to the percentage of loading. Both
conjugations contribute to the overall anti-HIV activity
after hydrolysis of the conjugate to the parent
nucleosides.
CS exhibited approximately 10-fold higher activity
against X4 virus (IIIB strain, IC50 = 5.9 µg/ml)) than R5
virus (BaL strain, IC50 = 62.5 µg/ml) (Table 1). These
data were consistent with previously reported data on
the weaker antiviral potency of anionic substances
against macrophage-tropic R5 HIV-1.8,14,15 X4 strains
possess higher number of positive charges on the V3
loop of gp120 compared to those of R5 strains, making
them more susceptible to inhibition by anionic
polymers.
In the present study, cellulose sulfate was
conjugated with NRTIs, AZT, FLT, and 3TC, through
different linkers to synthesize CS-nucleoside conjugates
as bifunctional anti-HIV agents targeting different
events in HIV life cycle. The conjugates were evaluated
for their anti-HIV activity against lab-adapted, X4 and
R5, cell-free HIV and wild-type and MDR clinical
isolates and for contraceptive properties in an animal
model. Cytotoxicity assays exhibited that none of the
conjugates and the corresponding physical mixtures
were cytotoxic at the highest concentration tested of 100
µg/mL.
Table 1 shows the antiviral activities of the
cellulose sulfate-nucleoside conjugates with different
loading percentages compared to those of CS, AZT, and
FLT. Conjugation of CS with nucleosides improved CS
antiviral activity against R5 strains.
Nucleoside-CSA conjugates (AZT-CSA, 3, 1.78%;
FLT-CSA, 4, 1.43%) demonstrated higher anti-HIV
activity than that of CS (1). The improved anti-HIV
activity of 3 (IC50 = 8.1 µg/mL) and 4 and 4 (IC50 = 1.5
µg/mL) compared to CS (IC50 = 62.5 µg/ml) could be
due to the release of two anti-HIV agents with different
mechanisms of action and/or the presence of additional
negatively charged acetate in the structure. Cellulose
sulfate-acetate (2) was tested for anti-HIV activity as a
control. Similar to 3 and 4, CSA (2) exhibited higher
potency than CS (1), especially against the R5 strain,
and surprisingly it was almost equally active to 3 and 4.
The higher activity of 2 and its conjugates, 3 and 4, may
be attributed to the presence of free negatively-charged
carboxylate groups from the acetate groups substituted
on CS, which enhance the overall negative charge
density of the molecule. Although the substitution of
acetate group on cellulose sulfate increased the antiHIV activity of CS, cellulose acetate (14) was

completely inactive (Table 2), suggesting that the
presence of sulfate is critical in maintaining the antiHIV activity of the polymer.
Compared with AZT-CSA and FLT-CSA
conjugates, 3TC-CSA (5, 1.07% loading) showed a
significantly different anti-HIV profile. Conjugate 5
revealed almost 37-fold less anti-HIV activity against
X4 strain when compared with 3. The poor anti-HIV
activity of 3TC conjugate could be due to the possible
intermolecular interaction of free positively charged 4amino group of 3TC with the negatively-charged groups
on CSA, which reduced the available free negative
charge of the conjugate for binding to V3 loops of the
virus.
Table 1. Anti-HIV activity of nucleoside-cellulose sulfate conjugates.
Compd
Chemical Name
Cytotoxicity
Antiviral
(% loading)
Activity
IIIB
BaL
Sodium Cellulose Sulfate
>100
5.9
62.5
1
(Mol. wt. 2,000,900 Da)
Cellulose Sulfate Acetate
>100
1.3
1.8
2
(CSA)
AZT-Cellulose Sulfate
>100
2.5
8.1
3
Acetate
(AZT-CSA, 1.78%)
FLT-Cellulose Sulfate
>100
2.3
1.5
4
Acetate
(FLT-CSA, 1.43%)
3TC-Cellulose Sulfate
>100
92.4
75.1
5
Acetate
(3TC-CSA, 1.07%)
AZT-Succinate-Cellulose
>100
2.2
9.9
6
Sulfate
(AZT-Suc-CS, 18.48%)
FLT-Succinate-Cellulose
>100
6.2
6.1
7
Sulfate
(FLT-Suc-CS, 7.87%)
Zidovudine
>100
2.4
4.2
AZT
Alovudine
>100
FLT
<0.1
<0.1
Lamivudine
>100
7.5
2.6
3TC
Anti-HIV activity of compounds evaluated in single-round infection
assays using HIV-1 IIIb (X4) and BaL (R5) and Galactosidase-transfected
P4R5 cell line. Data are expressed as IC50 (antiviral) or CC50 (cytotoxicity)
in µg/mL.

To determine the contribution of sulfate group in
generating anti-HIV activity of CS, cellulose phosphate
and dextran acetate were studied as controls. These
compounds were found to be totally inactive in viral
inhibition assays (Table 2), suggesting that negativelycharged acetate and phosphate alone are not sufficient
for efficient interaction with HIV gp120 V3 loop.
The anti-HIV activity of nucleoside-succinate-CS
conjugates, AZT-succinate-CS (6, 18.48%) and FLTsuccinate-CS (7, 7.87%) was also evaluated. Both
conjugates demonstrated at least 6-fold higher anti-HIV
activity against R5 strains than CS, suggesting the
contribution of the nucleoside analog in anti-HIV
activity (Table 1).
Although 6 and 7 had 10 and 6 times higher loading
values than the corresponding conjugates substituted
with acetate (3 and 4), respectively, the cellulose sulfate
succinate conjugates were generally less active than

cellulose sulfate acetate conjugates (Table 1). The lower
anti-HIV activity of conjugates containing succinate
linker, despite of their higher nucleoside loading,
compared to those containing acetate linker could be
due to incomplete hydrolysis of 6 and 7 to parent
nucleosides or the hydrolysis of the conjugate to
generate inactive nucleoside-succinate derivatives
instead of free nucleosides. Furthermore, upon
hydrolysis of conjugates containing acetate linker, the
acetate group will remain intact on the CS, contributing
to the overall negative charge of the anionic polymer.
The acetate is attached CS through methylene group and
cannot be hydrolyzed like succinate ester conjugate.
Further studies on the stability of the conjugates in vitro
and in vivo will provide insights about the amount of the
parent nucleosides and CS or CSA released and
correlation with the anti-HIV activity.
Table 2 shows the anti-HIV activity of the
nucleoside-CS conjugates compared with the
corresponding physical mixtures. The physical mixture
of AZT (1.78%) + CSA (8) showed slightly better antiHIV activity against HIV than the corresponding AZTCSA conjugate (3). When CSA in 8 was replaced by CS
in the physical mixture with AZT in 11 (18.48%), the
anti-HIV activity was significantly reduced even with a
higher loading of AZT in 11 because of the overall
reduction of negative charge density in CS and the
major contribution of CSA in overall activity.
Table 2. Anti-HIV activities of cellulose acetate, dextran acetate,
cellulose phosphate, and physical mixtures of nucleosides with CS, CSA,
and cellulose.
Chemical Name
Cytotoxicity
Antiviral Activity
Compd
(% loading)
IIIB
BaL
AZT (1.78 %) + CSA
>100
1.7
2.5
8
FLT (1.43 %) + CSA
>100
0.7
0.3
9
3TC (1.07%) + CSA
>100
0.7
1.7
10
AZT (18.48%) + CS
>100
16.2
15.3
11
FLT (1.43 %) + CS
>100
6.2
7.1
12
FLT (7.85 %) + CS
>100
0.7
0.3
13
Cellulose Acetate
>100
>100
>100
14
Dextran Acetate
>100
>100
>100
15
Cellulose Phosphate
>100
72.1
>100
16
AZT (1.78%) +
>100
75.5
8.5
17
Cellulose Acetate
FLT (1.43%) +
>100
6.8
6.5
18
Cellulose Acetate
3TC (1.07%) +
>100
73.9
22.4
19
Cellulose Acetate
Anti-HIV activity of compounds evaluated in single-round infection
assays using HIV-1 IIIb (X4) and BaL (R5) and Galactosidase-transfected
P4R5 cell line. Data are expressed as IC50 (antiviral) or CC50 (cytotoxicity)
in µg/mL.

FLT-CSA conjugate (4) and 3TC-CSA (5) were
compared with the corresponding physical mixtures, 9
and 10, respectively. Similarly FLT-CSA conjugate (4)
and 3TC-CSA (5) were less potent than their
corresponding physical mixtures, 9 and 10. Physical
mixture of CSA and FLT (9, 1.43%) exhibited
approximately 3-5 fold higher anti-HIV activity against

VBI (cell-free virus) when compared with the
corresponding FLT-CSA conjugate (4, 1.43%). In the
case of 10, the free amino group was not able to reduce
the anionic interactions of sulfate group as described
above in the conjugate 5. In general, the physical
mixtures of 8, 9, and 10 exhibited better anti-HIV
activity against HIV than the corresponding conjugates,
3, 4, and 5, respectively, possibly because of the
contribution of free negatively-charged acetate group of
CSA in the physical mixtures. This is further confirmed
by the fact physical mixtures containing CS (11, 12)
were significantly less potent than those containing
CSA (8, 9).
Similarly, the overall anti-HIV activity of 9 was
reduced by 8-22 times against when CSA in 9 (1.43%)
was replaced with CS in 12 (1.43%), suggesting the
importance of CSA in overall anti-HIV activity of these
conjugates.
Confirming the importance of the sulfate groups on
the cellulose backbone, the physical mixture of AZT +
cellulose acetate (17, 1.78%) showed significantly less
antiviral activity than AZT-CSA conjugate (3, 1.78%)
and AZT + CSA (8, 1.78%). Similarly, the physical
mixture of FLT + cellulose acetate (18, 1.43%) showed
9-21 fold less activity against cell-free virus when
compared with FLT + CSA (9, 1.43%). These results
were not surprising since cellulose acetate is an inactive
polymer and the percentage of AZT or FLT were low in
the physical mixture.
In general, the physical and chemical combination
of nucleosides with CS provided better antiviral activity
against both X4 and R5 HIV-1 strains. The
incorporation of acetate group on CS also improved
anti-HIV activity, possibly by creating new negative
charges after hydrolysis to free acetate groups on the
polymer. The succinate spacer was less optimal than the
acetate group for linking nucleosides and cellulose
derivatives.
AZT-CSA (3) and FLT-CSA (4) conjugates were
further evaluated for their anti-HIV activity against
wild-type (R5) and MDR clinical isolates and the data
were compared with controls, CS and nucleosides
(Table 3). CS (1) was active against MDR virus (IC50 =
1.61 µg/mL), but showed less activity against R5 wildtype (WT) HIV (IC50 > 20 µg/mL). Although FLT was
equally potent against these WT and MDR viruses, as
expected, AZT was less active against the MDR strain.

Table 3. Anti-HIV activities of AZT-CSA and FLT-CSA conjugates
against R5 and multidrug resistant HIV-1 clinical isolates.

Compd

Chemical Name

3

AZT-CSA (1.78%)

Type of Virus

IC50 (µg/mL)

R5

3.52

FLT-CSA (1.43%)

4

MDR

4.22

R5

2.67

MDR

0.50

R5

>20.0

MDR

1.61

CS

1

R5
0.03
AZT
Zidovudine
MDR
0.3
R5
0.002
FLT
Alovudine
MDR
0.004
Assay endpoint = p24 level (ELISA); IC50 = The minimum drug
concentration that inhibits HIV-induced cytopathic effect by 50%,
calculated by using a regression analysis program for semilog curve
fitting. HIV-1 clinical isolates: R5 = 92TH014; MDR = Multidrug
resistant virus 7324-1.

On the other hand, AZT-CSA (3) showed almost
similar anti-HIV activity against R5 and MDR viruses.
Furthermore, AZT-CSA (3) was more effective than CS
against the R5 HIV-1 lab-adapted strain BaL.
Conjugation of CSA and nucleosides improved both the
R5 inhibitory activity of CS and the activity of AZT
against MDR viruses.
AZT-CSA conjugate (3) was selected for in vivo
contraceptive efficacy testing in rabbits. Ex vivo mixing
of CS and 3 prior to insemination of fertile female
rabbits prevented pregnancy in 100% of the animals
(Table 4). CS has been shown to display contraceptive
properties and this result indicates that the contraceptive
properties of CS are retained after AZT conjugation to
the polymer. Thus, nucleoside-CS conjugates may have
application as potential anti-HIV and contraceptive
agents.
Table 4. Contraceptive efficacy of AZT-CSA conjugate 3.
No. of
Group

Concentration

Pregnant

Pregnancy

(mg/ml)

females/to

rate (%)

Unlike AZT and other nucleosides not tested in this
study, the above-described conjugates were equally
active against MDR virus and R5 WT HIV, suggesting
a synergistic activity between entry and replication
inhibitory mechanisms afforded by CS and nucleoside
derivatives, respectively. A similar type of synergistic
activity, albeit mechanistically different, was reported
by Gantlett et al.28, when physically combining two
other polyanions, PRO2000 and dextran sulfate, with
other entry inhibitors such as the neutralizing antibody
IgG1b12, the peptide-based fusion inhibitor T20, the
CCR5 antagonist TAK779 and the cyanobacterial
protein cyanovirin-N.
These data demonstrate the feasibility of
conjugating potent anti-HIV nucleosides with polymeric
cellulose derivatives to produce compounds that display
antimicrobial and contraceptive properties. In addition
to enhanced antiviral activity against R5 and multidrug
resistant viruses, the CSA-nucleoside combinations
showed in vivo contraceptive activity, laying the
foundation for the development of novel, dualprotection products.
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CS conjugates of AZT and FLT with acetate linker
(AZT-CSA (3) and FLT-CSA (4)) and the physical
mixture of AZT or FLT with CSA (8 and 9) exhibited
higher anti-HIV activity than their corresponding
conjugates with succinate linker (AZT-succinate-CS (6)
and FLT-succinate-CS (7)), CS, and the physical
mixtures of CS + AZT or FLT (11 and 12), possibly due
to the creation of additional negative charges provided
by the carboxylic acid of the acetate group.
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